DNTH
Dianthus Therapeutics, Inc.
Biotechnology
Market Cap$3.19B
5Y Perf.-31.9%
Build Your Comparison
Side-by-side financial analysisDNTH
ALXO
Try popular comparisons:
Stock Comparison
DNTH vs ALXO
Revenue, margins, valuation, and 5-year total return — side by side.
ALXO
ALX Oncology Holdings Inc.
Biotechnology
Market Cap$82M
5Y Perf.-95.4%
DNTH vs ALXO — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot |  DNTH |  ALXO |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $3.19B | $82M |
| Revenue (TTM) | $1M | $0.00 |
| Net Income (TTM) | $-11M | $-89M |
| Gross Margin | 94.3% | — |
| Operating Margin | -143.2% | — |
| Total Debt | $1M | $5M |
| Cash & Equiv. | $51M | $16M |
DNTH vs ALXO — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
DNTH
ALXO
| Stock | Jul 20 | Jun 26 | Return |
|---|---|---|---|
| Dianthus Therapeuti… (DNTH) | 100 | 68.1 | -31.9% |
| ALX Oncology Holdin… (ALXO) | 100 | 4.6 | -95.4% |
Price return only. Dividends and distributions are not included.
Quick Verdict: DNTH vs ALXO
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: DNTH leads in 3 of 6 categories, making it the strongest pick for capital preservation and lower volatility and recent price momentum and sentiment. ALX Oncology Holdings Inc. is the stronger pick specifically for growth and revenue expansion and profitability and margin quality. As sector peers, any of these can serve as alternatives in the same allocation.
🥇DNTH emerged as the overall leader. Track its performance:
DNTH
Dianthus Therapeutics, Inc.
The Income Pick
DNTH carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- beta 1.29
- -67.1% 10Y total return vs ALXO's -94.9%
- Lower volatility, beta 1.29, Low D/E 0.3%, current ratio 13.32x
Best for: income & stability and long-term compounding
ALXO
ALX Oncology Holdings Inc.
The Growth Play
ALXO is the clearest fit if your priority is growth exposure.
- EPS growth 26.4%
- 31.7% revenue growth vs DNTH's -67.3%
- 4.0% margin vs DNTH's -8.5%
Best for: growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth |  ALXO | 31.7% revenue growth vs DNTH's -67.3% |
| Quality / Margins | ALXO | 4.0% margin vs DNTH's -8.5% |
| Stability / Safety |  DNTH | Beta 1.29 vs ALXO's 1.49, lower leverage |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | DNTH | +321.9% vs ALXO's +177.1% |
| Efficiency (ROA) | DNTH | -1.7% ROA vs ALXO's -85.6%, ROIC -34.4% vs -122.0% |
DNTH vs ALXO — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2025
Segment breakdown not available.
DNTH vs ALXO — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLDNTHLAGGINGALXO
ALXOALX Oncology Holdings…
1leads
DNTHDianthus Therapeutics…
3leads
6 Total Categories
CATEGORYLEADERvs ALXOMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
ALXO1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
DNTH7/7
Total Returns1Y, 3Y, 5Y total returns with dividends
DNTH6/6
Risk & VolatilityBeta, volatility, and downside exposure
DNTH2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
ALXO leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
DNTH and ALXO operate at a comparable scale, with $1M and $0 in trailing revenue.
| Metric | DNTHDianthus Therapeu… | ALXOALX Oncology Hold… |
|---|---|---|
| RevenueTrailing 12 months | $1M | $0 |
| EBITDAEarnings before interest/tax | -$191M | -$91M |
| Net IncomeAfter-tax profit | -$11M | -$89M |
| Free Cash FlowCash after capex | -$130M | -$78M |
| Gross MarginGross profit ÷ Revenue | +94.3% | — |
| Operating MarginEBIT ÷ Revenue | -143.2% | — |
| Net MarginNet income ÷ Revenue | -8.5% | — |
| FCF MarginFCF ÷ Revenue | -97.7% | — |
| Rev. Growth (YoY)Latest quarter vs prior year | -60.2% | — |
| EPS Growth (YoY)Latest quarter vs prior year | -3.7% | +43.1% |
ALXO leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — DNTH and ALXO each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | DNTHDianthus Therapeu… | ALXOALX Oncology Hold… |
|---|---|---|
| Market CapShares × price | $3.2B | $82M |
| Enterprise ValueMkt cap + debt − cash | $3.1B | $71M |
| Trailing P/EPrice ÷ TTM EPS | -18.20x | -0.80x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 1567.68x | — |
| Price / BookPrice ÷ Book value/share | 5.86x | 3.14x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — DNTH and ALXO each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
DNTH leads this category, winning 7 of 7 comparable metrics.
Profitability & Efficiency
DNTH delivers a -1.8% return on equity — every $100 of shareholder capital generates $-2 in annual profit, vs $-124 for ALXO. DNTH carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to ALXO's 0.20x.
| Metric | DNTHDianthus Therapeu… | ALXOALX Oncology Hold… |
|---|---|---|
| ROE (TTM)Return on equity | -1.8% | -124.1% |
| ROA (TTM)Return on assets | -1.7% | -85.6% |
| ROICReturn on invested capital | -34.4% | -122.0% |
| ROCEReturn on capital employed | -41.6% | -127.0% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 2 |
| Debt / EquityFinancial leverage | 0.00x | 0.20x |
| Net DebtTotal debt minus cash | -$50M | -$11M |
| Cash & Equiv.Liquid assets | $51M | $16M |
| Total DebtShort + long-term debt | $1M | $5M |
| Interest CoverageEBIT ÷ Interest expense | — | -58.09x |
DNTH leads this category, winning 7 of 7 comparable metrics.
Total Returns (Dividends Reinvested)
DNTH leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in DNTH five years ago would be worth $4,126 today (with dividends reinvested), compared to $255 for ALXO. Over the past 12 months, DNTH leads with a +321.9% total return vs ALXO's +177.1%. The 3-year compound annual growth rate (CAGR) favors DNTH at 89.0% vs ALXO's -44.2% — a key indicator of consistent wealth creation.
| Metric | DNTHDianthus Therapeu… | ALXOALX Oncology Hold… |
|---|---|---|
| YTD ReturnYear-to-date | +92.7% | +32.2% |
| 1-Year ReturnPast 12 months | +321.9% | +177.1% |
| 3-Year ReturnCumulative with dividends | +574.8% | -82.6% |
| 5-Year ReturnCumulative with dividends | -58.7% | -97.5% |
| 10-Year ReturnCumulative with dividends | -67.1% | -94.9% |
| CAGR (3Y)Annualised 3-year return | +89.0% | -44.2% |
DNTH leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
DNTH leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
DNTH is the less volatile stock with a 1.29 beta — it tends to amplify market swings less than ALXO's 1.49 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. DNTH currently trades 79.2% from its 52-week high vs ALXO's 57.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | DNTHDianthus Therapeu… | ALXOALX Oncology Hold… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.29x | 1.49x |
| 52-Week HighHighest price in past year | $96.50 | $2.66 |
| 52-Week LowLowest price in past year | $16.64 | $0.40 |
| % of 52W HighCurrent price vs 52-week peak | +79.2% | +57.1% |
| RSI (14)Momentum oscillator 0–100 | 37.8 | 27.9 |
| Avg Volume (50D)Average daily shares traded | 674K | 1.1M |
DNTH leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates DNTH as "Buy" and ALXO as "Buy". Consensus price targets imply 163.2% upside for ALXO (target: $4) vs 46.4% for DNTH (target: $112).
| Metric | DNTHDianthus Therapeu… | ALXOALX Oncology Hold… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $111.91 | $4.00 |
| # AnalystsCovering analysts | 10 | 7 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
DNTH leads in 3 of 6 categories (Profitability & Efficiency, Total Returns). ALXO leads in 1 (Income & Cash Flow). 1 tied.
Best OverallDianthus Therapeutics, Inc. (DNTH)Leads 3 of 6 categories
Loading custom metrics...
DNTH vs ALXO: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is DNTH or ALXO a better buy right now?
Analysts rate Dianthus Therapeutics, Inc.
(DNTH) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — DNTH or ALXO?
Over the past 5 years, Dianthus Therapeutics, Inc.
(DNTH) delivered a total return of -58. 7%, compared to -97. 5% for ALX Oncology Holdings Inc. (ALXO). Over 10 years, the gap is even starker: DNTH returned -67. 1% versus ALXO's -94. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — DNTH or ALXO?
By beta (market sensitivity over 5 years), Dianthus Therapeutics, Inc.
(DNTH) is the lower-risk stock at 1. 29β versus ALX Oncology Holdings Inc. 's 1. 49β — meaning ALXO is approximately 15% more volatile than DNTH relative to the S&P 500. On balance sheet safety, Dianthus Therapeutics, Inc. (DNTH) carries a lower debt/equity ratio of 0% versus 20% for ALX Oncology Holdings Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — DNTH or ALXO?
On earnings-per-share growth, the picture is similar: ALX Oncology Holdings Inc.
grew EPS 26. 4% year-over-year, compared to -64. 7% for Dianthus Therapeutics, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — DNTH or ALXO?
ALX Oncology Holdings Inc.
(ALXO) is the more profitable company, earning 0. 0% net margin versus -79. 7% for Dianthus Therapeutics, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ALXO leads at 0. 0% versus -87. 4% for DNTH. At the gross margin level — before operating expenses — DNTH leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — DNTH or ALXO?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is DNTH or ALXO better for a retirement portfolio?
For long-horizon retirement investors, Dianthus Therapeutics, Inc.
(DNTH) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 29)). Both have compounded well over 10 years (DNTH: -67. 1%, ALXO: -94. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between DNTH and ALXO?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.